Dr. Helen Sabzevari Ph.D.
As President and CEO of Precigen and a member of its Board of Directors, Dr. Helen Sabzevari brings extensive expertise in research and development of immunotherapy-based therapeutics and in translating novel treatments from pre-clinical stage into the clinic. Prior to joining Precigen, she co-founded and served as chief scientific officer of Compass Therapeutics, a fully integrated drug discovery and development company focused on manipulating the immune system to treat human disease. Earlier in her career, Helen was senior vice president of Immuno-Oncology as well as Global Head of Immunotherapy, Oncology, Global Research and Early Development at EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany). She is the recipient of numerous awards including the National Institutes of Health Merit Award, the PharmaVOICE 100 Award and the Society for Immunotherapy of Cancer Team Science Award. Helen has a Doctorate in Cell and Molecular Immunology and a Postdoctorate in Immunology from The Scripps Research Institute.
Year appointed: 2020